Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

Clinical Observation of CHD Phlegm and Blood-stasis Syndrome Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02967718

Enrollment

13000

Registered

2016-11-18

Start date

2016-09-30

Completion date

2017-12-31

Last updated

2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Brief summary

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Detailed description

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

35 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy or metabolism syndrome people * Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion criteria

* Any inflammation, fever, trauma, burn or operation within 1 week * Obstructive pulmonary disease * Cerebral vascular disease * Severe renal or hepatic dysfunction * Malignant neoplasms * Hematopoietic system disease * Sever mental disease

Design outcomes

Primary

Measure	Time frame
all cause mortality	6 months

Countries

China

Contacts

Primary ContactWeiming Xu, Doctor

dreameng2008@126.com86-15652608470

Outcome results